【摘要】 绿色发展已成为我国的基本国策,我国作为原料药制造大国,传统的生产方式"三废"排放量大,使制药工业面临严峻的环保问题挑战,发展清洁生产技术是解决制药工业可持续发展的关键。酶催化技术具有选择性高、效率高、污染低等优势,是绿色制药技术的重要发展方向,以绿色酶法技术替代高污染的化学法技术备受关注。针对发酵类制药产品,包括β-内酰胺类抗生素中间体及其衍生原料药、维生素C衍生物和他汀类药物,总结了酶法技术的研究与应用进展,并对其未来发展进行了展望。更多还原

【Abstract】 Green development has become a basic state policy of China. As a major manufacturing country of active pharmaceutical ingredient(API), China’s pharmaceutical industry is facing seriously environmental challenges due to huge amount of "three wastes" generated from traditional production process. The development of clean production technology is the key to support the sustainable development of Chinese pharmaceutical industry. Enzymatic catalysis technology has advantages such as high selectivity, high efficiency and low pollution, and it is considered as an important development direction of green pharmaceutical technology. In recent years, the replacement of highly polluting chemical synthesis by green enzymatic synthesis has been attracted increasingly. This paper summarized the progress of research and application of enzymatic catalysis technology in fermentative pharmaceuticals including β-lactam antibiotic intermediates and their derivative APIs, vitamin C derivatives and statins. Furthermore, the perspective of this technology was provided.更多还原